A major breakthrough in the fight against COVID-19 has been announced by the pharmaceutical company Pfizer. The company has reported that their vaccine candidate has shown to be more than 90% effective in preventing the virus.
This news has brought hope to the world as the pandemic continues to ravage countries and economies. The vaccine, developed in partnership with German company BioNTech, is currently in the final stages of testing and is expected to be available for emergency use by the end of the year.
According to Pfizer’s CEO, Dr. Albert Bourla, this is a “great day for science and humanity.” The company’s initial analysis of the vaccine’s effectiveness was based on 94 confirmed cases of COVID-19 among the trial’s 43,538 participants. Out of these cases, only 8 were among those who received the vaccine, while the remaining 86 were in the placebo group.
The vaccine has also shown to be well-tolerated, with no serious safety concerns reported. The most common side effects were fatigue and headache, which were reported by less than 2% of participants.
While this news is certainly promising, experts caution that more data is needed to fully understand the vaccine’s effectiveness and safety. The trial will continue until there are 164 confirmed cases of COVID-19 among participants, which is expected to happen by the end of November.
In the meantime, Pfizer plans to apply for emergency use authorization from the US Food and Drug Administration (FDA) once they have collected the required safety data. The company also plans to produce up to 50 million doses of the vaccine in 2020 and up to 1.3 billion doses in 2021.
This development has sparked optimism and renewed efforts in the fight against the pandemic. However, health officials remind the public to continue following safety measures such as wearing masks and social distancing until a vaccine is widely available.
The world is eagerly awaiting more updates on this promising vaccine and its potential to bring an end to the global health crisis.
